Vincenzo Pavone
A5069053301- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Monoclonal and Polyclonal Antibodies Research
- Fungal Infections and Studies
- Radiopharmaceutical Chemistry and Applications
- Polyomavirus and related diseases
- Cancer therapeutics and mechanisms
- Cancer Genomics and Diagnostics
- Reproductive System and Pregnancy
- Glycosylation and Glycoproteins Research
- Medical Imaging Techniques and Applications
University of Catania
2025
Istituti di Ricovero e Cura a Carattere Scientifico
2005-2024
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2021-2024
Vita-Salute San Raffaele University
2021-2024
IRCCS Humanitas Research Hospital
2023
Azienda ospedaliera "Bianchi-Melacrino-Morelli"
2023
University of Siena
2020
Fondazione Gimema Onlus
2009-2020
Steelcase (United States)
2019
Instituto de Políticas y Bienes Públicos
2019
Purpose Primary testicular lymphoma (PTL) has poor prognosis with failures in contralateral testis, CNS, and extranodal sites. To prevent these events, we designed an international phase II trial (International Extranodal Lymphoma Study Group 10 [IELSG-10]) that addressed feasibility activity of conventional chemoimmunotherapy associated CNS prophylaxis testis irradiation. The was conducted by the IELSG Italian Foundation. Patients Methods Fifty-three patients (age 22 to 79 years) untreated...
In this multicenter, prospective, randomized clinical trial on advanced Hodgkin's lymphoma (HL), the efficacy and toxicity of two chemotherapy regimens, doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone (Stanford V) procarbazine, prednisone, epidoxirubicin, lomustine, vindesine (MOPPEBVCAD), were compared with dacarbazine (ABVD) as standard therapy to select which regimen would best support a reduced radiotherapy program, was limited < or = sites either...
Purpose The clinical impact of positron emission tomography (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgkin lymphoma, terms providing a rationale to shift who respond poorly onto more intensive regimen (PET response-adapted therapy), remains be confirmed. Patients and Methods phase II part the multicenter HD0801 study involved 519 de novo lymphoma received an initial treatment doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) underwent...
The efficacy of azacitidine for the treatment high-risk myelodysplastic syndromes has prompted issue its potential role even in acute myeloid leukemia (AML).The authors analyzed 82 patients with AML who were diagnosed according to World Health Organization criteria. median patient age was 72 years (range, 29-87 years), and 27 (33%) had secondary AML. Of 62 evaluable cytogenetics, 18 (29%) a poor-risk karyotype, 44 (71%) an intermediate karyotype. Thirty-five (43%) received as front-line...
Although high-dose therapy and autologous stem cell transplant combined with novel agents continues to be the hallmark of first-line treatment in newly diagnosed transplant-eligible multiple myeloma patients, impact tandem or autologous/reduced-intensity allogeneic for patients extramedullary disease (EMD) high-risk cytogenetics is not yet defined. Here, we analyzed clinical cytogenetic data from 488 adult EMD undergoing single (n = 373), 84), autologous-allogeneic 31) between 2003 2015. At...
To determine whether autologous hematopoietic stem cell transplantation (aHSCT) is able to induce durable disease remission in people with multiple sclerosis (MS), we analyzed the long-term outcomes after a large cohort of patients MS.To be included, minimum dataset (consisting age, MS phenotype, Expanded Disability Status Scale [EDSS] score at baseline, information on technology, and least 1 follow-up visit transplantation) was required.Two hundred ten were included (relapsing-remitting...
PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients follicular lymphoma who responded to induction immunochemotherapy. METHODS randomly assigned treatment-naïve, advanced-stage, high-tumor burden receive standard RM or on the basis metabolic response and molecular assessment minimal residual disease (MRD). The experimental arm used three types therapies: for complete (CMR) MRD-negative patients, observation; CMR MRD-positive...
Correct definition of the level risk invasive fungal infections is first step in improving targeting preventive strategies. We investigated potential relationship between pre-hospitalization exposure to sources fungi and development adult patients with newly diagnosed acute myeloid leukemia after their course chemotherapy. From January 2010 April 2012, all consecutive 33 Italian centers were prospectively registered. Upon admission, information about possible pre-chemotherapy factors...
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy followed by granulocyte-colony stimulating factor (G-CSF), in 37 multiple myeloma (MM) or lymphoma patients, who were candidates for autologous stem cell transplantation (ASCT) predicted as poor mobilizers (PMs). Patients identified PMs according history a previously failed mobilization attempt presence ≥1 factors predicting an unsuccessful harvest, such advanced disease, prior extensive...
Background Although the efficacy of plerixafor in peripheral blood stem cell ( PBSC ) mobilization has been explored several studies, factors associated with successful after administration granulocyte–colony‐stimulating factor G ‐ CSF ), or without chemotherapy, have not investigated. We analyzed data on from a large Italian database lymphoma and myeloma plerixafor‐treated patients. Study Design Methods Two endpoints were established to define mobilization: patients at least 2 × 10 6 CD 34+...
Despite improvements in standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for patients untreated, diffuse large B-cell lymphoma, up to 40% of these relapse. Lenalidomide alone or combination rituximab has been shown be active relapsed/refractory aggressive lymphomas. In this phase I study we determined the maximum tolerated dose lenalidomide plus elderly (median age 68 years) lymphoma. Four doses (5, 10, 15, 20 mg/day on days 1–14) allocated using...
Minimal residual disease (MRD) analysis is a known predictive tool in mantle cell lymphoma (MCL). We describe MRD results from the Fondazione Italiana Linfomi phase 3 MCL0208 prospective clinical trial assessing lenalidomide (LEN) maintenance vs observation after autologous stem transplantation (ASCT) first comprehensive of different techniques, molecular markers, and tissues (peripheral blood [PB] bone marrow [BM]), taken at well-defined time points. Among 300 patients enrolled, marker was...
Polydactyly and syndactyly, which are commonly encountered congenital limb deformities, rarely occur together linked with significant genetic mutations. This report sheds light on a unique co-presentation involving mutations in both the GLI3 TBX5 genes, offering deeper understanding of interactions that may influence development. case is important to increase our knowledge bases malformations. We an 8-month-old boy, born non-consanguineous parents, presenting polydactyly syndactyly his...
Post-transplant high-dose cyclophosphamide (PTCy) is effective in overcoming the negative impact of HLA disparity haploidentical setting. In light these results, we investigated efficacy and safety PTCy, with a calcineurine inhibitor mycophenolate mofetil, improving clinical outcomes haematopoietic cell transplantation (HCT) from mismatched unrelated donor (MMUD) patients acute myeloid malignancies by reducing aGvHD incidence severity. A prospective single arm, phase II study (PHYLOS -...